Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen, David R. Macdonald, David A. Reardon et al. · Journal of Clinical Oncology · 2010 · 3.8K citations · Full text

Medicine, Neurology, Oncology +15

<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

Alba A. Brandes, Enrico Franceschi, Alicia Tosoni et al. · Journal of Clinical Oncology · 2008 · 831 citations · Full text

Medicine, Oncology, Radiology +17

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Marc C. Chamberlain, Michael Glantz, Lisa Chalmers et al. · Journal of Neuro-Oncology · 2006 · 341 citations

Medicine, Oncology, Radiation Oncology +14

Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas

Walter Rachinger, Claudia Goetz, Gabriele Pöpperl et al. · Neurosurgery · 2005 · 288 citations

Medicine, Oncology, Radiology +17

Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis

Thomas Mikeska, Christoph Bock, Osman El‐Maarri et al. · Journal of Molecular Diagnostics · 2007 · 240 citations · Full text

Life Sciences, Biotechnology, Molecular Biology +9